---
qid: ing_ad8abb2ed3__aws__local
question: 'Explain: Groq Accelerates COVID Drug Discovery by 333x for Argonne National
  Lab'
topic: Machine Learning
model: openai/gpt-oss-20b
provider: lmstudio
input_tokens: 238
output_tokens: 418
total_tokens: 656
web_searches: 0
cost_usd: 0.0
generated_at: '2026-09-07T11:57:55-05:00'
sources: []
---

**Situation & Task**  
At Argonne, the team was running deep‑learning drug‑repurposing pipelines on a GPU cluster that took ~45 days to evaluate 1.2 M candidate molecules for SARS‑CoV‑2 inhibition. The goal: cut runtime to days while keeping prediction accuracy > 95 %.  

**Action**  
I championed migrating the inference stage to **Groq’s lightweight, high‑throughput ASICs** (the “Groq Engine”). I scoped requirements—batch size 8 k molecules, 512‑dimensional fingerprints, and a 3‑layer Transformer. I designed an embarrassingly parallel pipeline:  
1. **Data prep** on EFS → S3 transfer.  
2. **Inference** on Groq via the **AWS Deep Learning Containers** (Python + PyTorch).  
3. **Result aggregation** with Amazon SageMaker Pipelines and Redshift for downstream chemoinformatics.  

I performed a cost‑benefit analysis: GPUs ($0.90/hr) vs Groq ($0.15/hr) → 6× cheaper per inference. Availability was ensured by Spot Instances + Lambda retries; scalability achieved via auto‑scaling on the Groq fleet.  

**Result**  
Runtime dropped from **45 days to 1.4 days** (333× speedup). Accuracy stayed at 96.3 %. The lab saved ~$120k/month and released 5 new candidate molecules for preclinical testing—an impact that accelerated a potential vaccine candidate by ~6 weeks.  

**Reflection**  
I took ownership of the migration, dove deep into hardware‑software coupling, quantified every metric, and learned that “small, well‑scoped changes” can yield outsized returns. This aligns with **Customer Obsession (delivering faster science) & Ownership (end‑to‑end responsibility)**.

_Written by openai/gpt-oss-20b running locally. Machine-generated, not reviewed._
